Edition:
United States

Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

0.82USD
28 Apr 2017
Change (% chg)

$-0.01 (-1.56%)
Prev Close
$0.83
Open
$0.82
Day's High
$0.83
Day's Low
$0.81
Volume
3,055,541
Avg. Vol
6,305,633
52-wk High
$8.49
52-wk Low
$0.73

NVAX.O

Chart for NVAX.O

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $221.94
Shares Outstanding(Mil.): 271.95
Dividend: --
Yield (%): --

Financials

  NVAX.O Industry Sector
P/E (TTM): -- 58.40 30.08
EPS (TTM): -1.03 -- --
ROI: -87.84 -0.42 13.25
ROE: -195.01 5.87 14.41

BRIEF-Novavax reports Q4 loss per share $0.21

* Novavax reports fourth quarter and year-end 2016 financial results

Feb 27 2017

BRIEF-Novavax reports Q3 loss per share $0.24

* Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S

Nov 09 2016

Novavax cuts jobs to push ahead with respiratory vaccine for elderly

Nov 9 Novavax Inc said on Wednesday it would cut 30 percent of its global workforce, or 164 jobs, to help fund the testing of its vaccine for a common respiratory virus in the elderly, about two months after failing a late-stage study.

Nov 09 2016

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF76.55 -0.35
Merck & Co., Inc. (MRK.N) $62.33 -0.25
Sanofi SA (SASY.PA) €86.61 +0.64
GlaxoSmithKline plc (GSK.L) 1,550.00 -8.50
AstraZeneca plc (AZN.L) 4,637.50 -60.50

Earnings vs. Estimates